Skip to main content
. 2022 Dec 7;2022(12):CD015477. doi: 10.1002/14651858.CD015477
Type of vaccine Reference ID Register Phase Vaccine Comparator Sample size Participants/centre/location
RNA‐based vaccine Roozen 2021 NL9275 1‐2 mRNA‐1273 20 μg ID mRNA‐1273 20 μg IM 30 Healthy adults/single centre/the Netherlands
Low 2021 NCT04480957 1‐2 ARCT‐021 
(1 μg; 5 μg; 7.5 μg; 10 μg)
Placebo 106 Healthy adults/single centre/Singapore
Li 2021b ChiCTR2000034825
NCT04523571
1 BNT162b1 10 μg BNT162b1 30 μg 144 Healthy young adults/single centre/China 
Mulligan 2020 NCT04368728 1‐2 BNT162b1 (10 μg; 30 μg; 100 μg) Placebo 45 Healthy adults/2 centres/USA
Non‐replicating viral vector Ramasamy 2020 NCT04400838; ISRCTN, 15281137 2/3 ChAdOx1 (2.2 × 1010 vp; 1 or 2 doses) MenACWY 300 Healthy adults/2 centres/UK
Inactivated virus Wu 2021c NCT04552366 1 Ad5‐nCoV 0.2 mL neb 2D Ad5‐nCoV (0.1 mL neb 2D; 0.5 mL IM + 0.2 mL neb; 0.5 mL IM; 1.0 mL IM) 130 Adults/single centre/China
 
Zhu 2020 NCT04341389 2 Ad5‐vectored (1 × 1011 vp; 5 × 1010 vp) Placebo 508 Healthy young adults/single centre/China
Zhu 2022 NCT04566770 2 Ad5‐vectored (3 × 1010 vp) Placebo 400 Healthy children and adolescents/single centre/China
Che 2021 NCT04412538 2 KMS‐1 (100 EU; 150 EU) D0/14; D0/28
KMS‐1
Placebo 750 Healthy adults/2 centres/China
Lazarus 2021 NCT04671017, ISRCTN 82411169 1‐2 VL A2001 3 AU
 
VL A2001 35 AU; 7 AU 153 Healthy adults/4 centres/UK
Pan 2021a NCT04758273 1 KCONVAC 5 μg KCONVAC 10 μg 60 Healthy adults/single centre/China
Pan 2021a NCT04756323 2 KCONVAC (5 μg; 10 μg)
(D0/14; D0/28)
Placebo 500 Healthy adults/single centre/China
Pitisuttithum 2021 NCT04764422 1 NDV‐HXP‐S (1 μg; 1 μg + CpG1018; 3 μg; 3 μg + CpG1018; 10 μg) Placebo 210 Healthy adults/single centre/Thailand
Pu 2021 NCT04412538 1 KMS‐1 100 EU D0/14; D0/28 Placebo 192 Healthy adults/single centre/China
Zakarya 2021 NCT04530357 1 QazCovid‐in Placebo 44 Healthy adults/single centre/Kazakhstan
Protein subunit Chappell 2021 NCT04495933 1 SARS‐CoV‐2 Sclamp 
(5 μg; 15 μg; 45 μg)
Placebo 120 Healthy adults/single centre/Australia
Goepfert 2021 NCT04537208 1‐2 CoV2 preS dTM LD + AFO3
CoV2 preS dTM LD + ASO3
CoV2 preS dTM HD + AFO3
CoV2 preS dTM HD + ASO3
CoV2 preS dTM HD
Placebo 271 Healthy adults/10 centres/USA
Hsieh 2021 NCT04695652 2 MVC‐COV1901 Placebo 3854 Healthy adults/11 centres/Taiwan
Zhang 2021b ChiCTR2100045108 1 V‐01 (10 μg; 25 μg; 50 μg) Placebo 180 Healthy adults/single centre/China
Meng 2021b NCT04530656 1 Sf9 cells vaccine (low dose in 2 doses; high dose in 2 or 3 doses) Placebo 168 Healthy adults/single centre/China
Meng 2021b NCT04640402 2 Sf9 cells vaccine (low dose or high dose in 2 or 3 doses) Placebo 960 Healthy adults/single centre/China
Nguyen 2021 NCT04683484 2 Nanocovax 
(25 μg; 50 μg; 75 μg)
Placebo 560 Healthy adults/2 centres/Vietnam
Nguyen 2021 NCT04683484 1 Nanocovax 
(25 μg; 50 μg)
Nanocovax 75 μg 60 Healthy adults/2 centres/Vietnam
Richmond 2021 NCT04405908 1 SCB‐2019 
(3 μg; 3 μg + AS03; 3 μg + CpG/Alum; 9 μg; 9 μg + AS03 9 μg + CpG/Alum; 30 μg; 30 μg + AS03; 30 μg + CpG/Alu)
Placebo 151 Healthy adults/single centre/Australia
Ryzhikov 2021 NCT04527575 2 EpiVacCorona Placebo 86 Healthy adults/single centre/Russia
Shu 2021 ChiCTR2100045107 2 V‐01 (10 μg; 25 μg; 50 μg) Placebo 880 Healthy adults/single centre/China
Sridhar 2021 NCT04762680 2 CoV2 preS dTM (15 µg; 10 µg) CoV2 preS dTM 5 µg 722 Adults with and without prior SARS‐CoV‐2 infection and risk factors for severe disease/20 centres/USA and Honduras
Yang 2021 NCT04466085 2 ZF2001 (25 μg 2 doses; 50 μg 2 doses; 25 μg 3 doses; 50 μg 3 doses) Placebo 900 Healthy adults/single centre/China
Yang 2021
 
NCT04445194 2 ZF2001 (25 μg 3 doses; 50 μg 3 dose) Placebo 50 Healthy adults/single centre/China
DNA‐based vaccine Mammen 2021 NCT04642638   INO‐4800 (1 mg; 2 mg) D0/28
 
Placebo 201 Healthy adults/19 centres/USA
Virus‐like particle (VLP) Gobeil 2021 NCT04636697   CoVLP 3.75 μg + AS03 Placebo 753 Healthy adults/multiple centres/Canada and USA 
Ward 2021b NCT04450004   CoVLP (3.75 μg with CpG1018, AS03 or without adjuvant; 7.5 μg with CpG1018, AS03 or without adjuvant; 15 μg with CpG1018, AS03 or without adjuvant) Placebo 180 Canada